Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Oncolytics Biotech® Reports 2018 First Quarter Results

CALGARY, Alberta and SAN DIEGO, May 11, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (TSX:ONC) (OTCQX:ONCYF), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced financial results and operational highlights for the quarter ended March 31, 2018.  All dollar amounts are Canadian unless otherwise noted.

“The rapid and exciting evolution of Oncolytics has continued in 2018. We have presented exciting immuno-oncology data at a number of medical meetings which supports both our rationale for a phase 3 registration study of pelareorep in metastatic breast cancer and additional collaborations using checkpoint inhibitors,” said Dr. Matt Coffey, President and CEO of Oncolytics Biotech. “With this momentum we have begun to lay the groundwork for value driving catalysts over the next 18 months, including multiple near-term clinical programs evaluating the efficacy of pelareorep in combination with checkpoint inhibitors in a variety of cancer indications. Finally, management also advanced plans to relist Oncolytics’ shares on the NASDAQ Capital Market exchange and we continue to carefully evaluate the timing of this action.”

Selected highlights since January 1, 2018

Clinical Updates

  • Presented posters highlighting data from pelareorep studies at the American Association for Cancer Research (AACR) Annual Meeting 2018. The presentations showed preclinical models demonstrating pelareorep increased PD-L1 expression in microsatellite stable (MSS) colorectal cancer cells (CRC) and demonstrated efficacy for pelareorep and anti-PD1 agent combination.
  • Presented positive pelareorep data in combination with Keytruda® and anti-CD73 at the International Oncolytic Virus Conference 2018. The poster highlighted the effectiveness of pelareorep in combination with Keytruda® and/or an anti-CD73 immunotherapy in prostate cancer cell lines.
  • Presented poster highlighting results from the REO 024 study at the 2018 Gastrointestinal Cancers Symposium sponsored by ASCO. The poster described six efficacy evaluable, second-line, pancreatic cancer patients, including two with stable disease of 126 and 277 days and remarkably, one patient that had a partial response and remained on study for 504 days, through 35 cycles of treatment.
  • Reached agreement with the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for the protocol design, clinical endpoints and statistical analysis approach for the company's phase 3 study evaluating pelareorep for the treatment of metastatic breast cancer.

Corporate Updates

  • Received shareholder approval for the consolidation of the Company's common shares, which will enable Oncolytics to meet requirements for listing on the NASDAQ Capital Market.

Anticipated Milestones

  • Initiate a phase 3 registration study of pelareorep in combination with paclitaxel, for the treatment HR+/HER2- mBC patients.
  • Initiate a phase 2 partner-sponsored window of opportunity study of pelareorep in combination with standard of care therapy in the neoadjuvant setting in mBC in 2H 2018.
  • Initiate multiple phase 2 partner-sponsored studies to generate important biomarker and efficacy data of pelareorep in combination with checkpoint inhibitors in 2H 2018.
  • Expand the findings of REO 024 by initiating a phase 2 study examining pelareorep in combination with pembrolizumab (KEYTRUDA®) in patients with relapsed metastatic adenocarcinoma of the pancreas.
  • Re-list on NASDAQ. 

Financial

  • At March 31, 2018, the Company reported $7.7 million in cash and cash equivalents.
  • As at May 3, 2018, we had an unlimited number of authorized common shares with 142,334,722 common shares issued and outstanding, 16,445,000 warrants with a $0.95 strike price and 11,339,608 options and share units.
 
ONCOLYTICS BIOTECH INC.
INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
(unaudited)
As atMarch 31,
2018
$
December 31,
2017
$
Assets  
Current assets  
Cash and cash equivalents7,745,255 11,836,119 
Contract receivable4,899,720 4,767,100 
Other receivables38,888 37,726 
Prepaid expenses1,087,013 1,176,063 
Total current assets13,770,876 17,817,008 
Non-current assets  
Property and equipment356,281 333,441 
Total non-current assets356,281 333,441 
   
Total assets14,127,157 18,150,449 

Liabilities And Shareholders’ Equity
  
Current Liabilities  
Accounts payable and accrued liabilities3,201,351 3,684,023 
Contract liability927,400 1,545,645 
Total current liabilities4,128,751 5,229,668 
Non-current liabilities  
Contract liability5,255,180 4,636,935 
Total non-current liabilities5,255,180 4,636,935 
   
Total liabilities9,383,931 9,866,603 

Shareholders’ equity
  
Share capital
 Authorized: unlimited
 Issued:
 March 31, 2018 – 142,325,222 
 December 31, 2017 – 141,805,722
272,230,453 271,710,138 
Warrants3,617,900 3,617,900 
Contributed surplus27,567,356 27,028,238 
Accumulated other comprehensive income444,351 373,730 
Accumulated deficit(299,116,834)(294,446,160)
Total shareholders’ equity4,743,226 8,283,846 
Total liabilities and equity14,127,157 18,150,449 


 
ONCOLYTICS BIOTECH INC.
INTERIM CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS
(unaudited)
 
For the three month period ending March 31,2018
$
2017
$
   
Expenses  
  Research and development2,934,891 2,268,071 
  Operating1,762,553 1,300,300 
Loss before the following(4,697,444)(3,568,371)
  Interest26,890 50,715 
Loss before income taxes(4,670,554)(3,517,656)
  Income tax expense(120)(63)
Net loss(4,670,674)(3,517,719)
Other comprehensive income (loss) items that may be
  reclassified to net loss
  
   Translation adjustment70,621 (20,748)

Net comprehensive loss
(4,600,053)(3,538,467)
Basic and diluted loss per common share(0.03)(0.03)
Weighted average number of shares (basic and diluted)142,249,733 121,258,222
 


 
ONCOLYTICS BIOTECH INC.
INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
(unaudited)
 
 Share Capital
$
Warrants
$
Contributed
Surplus
$
Accumulated
Other
Comprehensive
Income
$
Accumulated
Deficit
$
Total
$
As at December 31, 2016262,321,825  26,643,044 554,060 (278,829,309)10,689,620 
Net loss and other comprehensive loss   (20,748)(3,517,719)(3,538,467)
Share based compensation  133,889   133,889 
Share issue costs(10,500)    (10,500)
As at March 31, 2017262,311,325  26,776,933 533,312 (282,347,028)7,274,542 
       
As at December 31, 2017271,710,138 3,617,900 27,028,238 373,730 (294,446,160)8,283,846 
Net loss and other comprehensive income   70,621 (4,670,674)(4,600,053)
Issued pursuant to "At the Market" Agreement553,650     553,650 
Share based compensation  539,118   539,118 
Share issue costs(33,335)    (33,335)
As at March 31, 2018272,230,453 3,617,900 27,567,356 444,351 (299,116,834)4,743,226 


 
ONCOLYTICS BIOTECH INC.
INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)
 
For the three month period ending March 31,2018
$
2017
$
   
Operating Activities  
Net loss for the period(4,670,674)(3,517,719)
Amortization - property and equipment19,858 24,036 
Share based compensation539,118 133,889 
Unrealized foreign exchange (gain) loss(4,513)52,032 
Net change in non-cash working capital(492,547)(637,646)
Cash used in operating activities(4,608,758)(3,945,408)

Investing Activities
  
Acquisition of property and equipment(42,619)(5,836)
Redemption of short-term investments 2,088,800 
Cash (used in) provided by investing activities(42,619)2,082,964 

Financing Activities
  
Proceeds from "At the Market" equity distribution agreement520,315 (10,500)
Cash provided by (used in) financing activities520,315 (10,500)

Decrease in cash
(4,131,062)(1,872,944)
Cash and cash equivalents, beginning of period11,836,119 12,034,282 
Impact of foreign exchange on cash and cash equivalents40,198 (58,945)
Cash and cash equivalents, end of period7,745,255 10,102,393 
     

To view the Company's Fiscal 2018 First Quarter Consolidated Financial Statements, related Notes to the Consolidated Financial Statements, and Management's Discussion and Analysis, please see the Company's annual filings, which will be available under the Company's profile at www.sedar.com and on Oncolytics' website at http://www.oncolyticsbiotech.com/investor-centre/financials/.

About REOLYSIN/Pelareorep 
REOLYSIN, also known as pelareorep, is a non-pathogenic, proprietary isolate of the unmodified reovirus: a first-in-class intravenously delivered immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses to treat a variety of cancers.

About Oncolytics Biotech Inc.
Oncolytics is a biotechnology company developing REOLYSIN®, also known as pelareorep, an intravenously delivered immuno-oncolytic virus. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers. Oncolytics' clinical development program emphasizes three pillars: chemotherapy combinations to trigger selective tumor lysis and immuno-therapy and immune modulator (IMiD) combinations to produce innate and adaptive immune responses. Oncolytics is currently planning its first registration study in metastatic breast cancer, as well as studies in combination with checkpoint inhibitors and targeted and IMiD therapies in solid and hematological malignancies. For further information, please visit: www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as “forward-looking statements”). Forward-looking statements, including the Company's belief as to the potential and mode of action of REOLYSIN, also known as pelareorep, as a cancer therapeutic; and other statements related to anticipated developments in the Company's business and technologies involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.

Company Contact
Michael Moore
Vice President, Investor Relations & Corporate Communications
858-886-7813
[email protected]  

Investor Relations
Robert Uhl
Westwicke Partners
858-356-5932
[email protected]

Media Contact
Jason Spark
Canale Communications 
619-849-6005
[email protected]

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).